MARKET

PVCT

PVCT

Provectus Biopha
OTCMQB
0.049
-0.006
-10.58%
Closed 13:11 09/23 EDT
OPEN
0.055
PREV CLOSE
0.055
HIGH
0.055
LOW
0.049
VOLUME
150.18K
TURNOVER
8.14K
52 WEEK HIGH
0.078
52 WEEK LOW
0.042
MARKET CAP
20.56M
P/E (TTM)
-4.6226
1D
5D
1M
3M
1Y
5Y
Provectus inks option deal with university for antimicrobial device's use for eye infections
Provectus (OTC:PVCT) <a href="https://seekingalpha.com/pr/18947112-provectus-biopharmace...
Seekingalpha · 4d ago
Provectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infections
KNOXVILLE, TN, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has entered into an option agreement with the University of Miami (UM) for an exclusive worldwide license of intellectual property developed by the O...
GlobeNewswire · 4d ago
Provectus Biopharma partners to test rose bengal as anti-fungal and anti-oral bacterial agent
Provectus (OTC:PVCT) <a href="https://seekingalpha.com/pr/18915397-provectus-biopharmaceuticals...
Seekingalpha · 08/24 13:26
Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Tennessee Health Science Center to Investigate Pharmaceutical-Grade Rose Bengal as Anti-Fungal and Anti-Oral Bacterial Agent
KNOXVILLE, TN, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with Michio Kurosu, PhD, Professor, Department of Pharmaceutical Sciences at the College of Pharmacy of th...
GlobeNewswire · 08/24 13:00
Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia
KNOXVILLE, TN, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with Aru Narendran, MD, PhD, Professor, Departments of Pediatrics, Oncology, Biochemistry & Molecular Biol...
GlobeNewswire · 08/17 11:00
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repair
KNOXVILLE, TN, July 19, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Kelly Tseng, PhD, Associate Professor of Pathology and Lab Medicine, School of Life Sciences at th...
GlobeNewswire · 07/19 10:00
Provectus Biopharmaceuticals Presents Data from PV-10® Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congress
KNOXVILLE, TN, June 30, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that updated data from the Company’s initial expansion cohort of patients with uveal melanoma metastatic to the liver (mUM) in its cancers-of-the-liver Phase 1 trial o...
GlobeNewswire · 06/30 17:42
Provectus receives shareholders approval to go for reverse stock splits
Provectus (OTC:PVCT) stated Thursday it has received shareholders approval to execute reverse stock splits of its common and preferred shares in the same ratio along with the authorized share reduction. The reverse
Seekingalpha · 06/23 14:18
More
About PVCT
Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

Webull offers kinds of Provectus Biopharmaceuticals Inc stock information, including OTCMQB:PVCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PVCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PVCT stock methods without spending real money on the virtual paper trading platform.